LifeMD

2Mês·

LifeMD Q2 Earnings

$XDWH (-0,02%)
$IUHC (-0,05%)
$WHEA (-0,03%)
$WHCS (+0,47%)
$WELS (+0,05%)
$LLY (+0,54%)
$NOVO B (+0,13%)
$RNN519 (+0,19%)

❌ Earnings Miss

Adj. EPS: $(0.06) (vs. $(0.01) est)

YoY: ↓ 200.0% (from $0.06)

❌ Revenue Miss

Sales: $62.20M (vs. $66.34M est)

YoY: ↑ 22.8% (from $50.66M)

2 Comentários

Bubu@Bubu_98

2Mês

Not only hims has seasonal weakness ...

•

Mostrar resposta

BamBamInvest

@BamBamInvest

4Mês·

Health sector - What do you think?

I would be interested in your opinion on the healthcare sector ? I am currently toying with the idea of parking my cash in the $XDWH (-0,02%) in the health care sector. I believe that the healthcare sector has some catching up to do and if the stock market becomes more volatile, I think the healthcare sector will benefit. Even if it is perhaps only a short-term position, I expect a higher return here than on the call money account. I like the idea, especially as the market for slimming products should continue to grow strongly and $LLY (+0,54%) ubd $NOVO B (+0,13%) will benefit from this as a dominant player.

$HIMS (+1,27%)
$LFMD

18 Comentários

Tenbagger2024@Tenbagger2024

4Mês

I agree with Kennedy and a few negative news items have hurt the sector.
I also see a need to catch up here.
There are some pearls in the sector in particular that can benefit enormously from AI research.
If you don't want to go pearl hunting, an ETF is of course an alternative.

•

Ver todas as 7 restantes respostas

StonkSniffer

@ApezuColabooster

5Mês·

High expectations

Added another 300 stock (for a total of 800) of $LFMD with high hopes and expectations. Focus to sell is in 1-2 years, when the company is expected to turn profitable and I am assuming the valuation will jump a lot. May hold for longer, since company may have a bright future ahead of them.

5Mês·

LifeMD Q1 2025 - Earnings Highlights

$LFMD earnings highlights for Q1 2025:

Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70%
Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period
Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period
GAAP net income of $0.6 million or $0.01 per diluted share, delivering first-ever quarter of positive GAAP EPS
Raising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth

StonkSniffer

@ApezuColabooster

5Mês·

They say "do not time the market", but sometimes it works out beautifully.

StonkSniffer@ApezuColabooster

4 Comentários

5Mês

Also, please ignore the dots being in the "wrong" place. Nordea bank marks the transactions at the daily average instead of the actual transaction price.

••

5Mês·

LifeMD expands access to Wegovy ® for self-pay patients

LifeMD is expanding access to Wegovy ® for self-pay patients through its virtual care platform by integrating NovoCare ® pharmacy. Eligible patients can now receive all FDA-approved Wegovy doses for $499/month including home delivery - no insurance required.

Source: https://ir.lifemd.com/press-release-details.php?newsId=3070180

ir.lifemd.comLifeMD

6Mês·

LifeMD to Accept Medicare Beneficiaries for Qualifying Virtual Primary Care

LifeMD said Thursday it expanded its insurance acceptance to include Medicare beneficiaries for qualifying virtual primary care, including weight management programs.

The company said over 21 million Medicare Part B beneficiaries in 26 states now have access to virtual care services.

LifeMD said it targets to expand access to medical services to over 60 million Medicare beneficiaries across 49 states by the end of Q2.

LifeMD shares were up more than 2% in recent trading.

7Mês·

LifeMD quarterly highlights